This is a lung condition where the tiny air sacs in your lungs fill up with a thick, protein-like substance. This can cause coughing and difficulty breathing.
Every report comes from a Lived member, sent anonymously.
Have you tried Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Pulmonary Alveolar Proteinosis?
Pulmonary alveolar proteinosis (PAP) is a rare lung disease in which a fatty, protein-rich material called surfactant slowly fills the tiny air sacs (alveoli) of the lungs. Surfactant normally helps the air sacs stay open, and immune cells in the lungs called alveolar macrophages clear away the used material. In PAP that clearing process fails, so surfactant builds up and leaves less room for oxygen to pass into the blood. The usual first sign is shortness of breath with activity, which can gradually progress to breathlessness at rest. Some people also have a dry cough, fatigue, chest tightness or weight loss, and some have no symptoms at all when it is first found. Because these symptoms are common to many lung problems, PAP is often mistaken at first for asthma, COPD (chronic obstructive pulmonary disease) or pneumonia.
PAP is a syndrome with several distinct causes, and the cause shapes treatment. About 90% of cases are autoimmune PAP. In this form the immune system makes antibodies against GM-CSF (granulocyte-macrophage colony-stimulating factor), a signaling protein that the lung's macrophages need to mature and clear surfactant. With GM-CSF blocked, the macrophages fall behind and surfactant accumulates. Autoimmune PAP most often begins in people in their 20s to 40s and is extremely rare in children. Why the antibodies develop is not known, and it is not contagious. Secondary PAP, a small share of cases, develops because another illness or exposure impairs the macrophages. Blood and bone marrow disorders are the most common underlying cause; certain medicines, infections and heavy inhalation of toxic dusts or fumes are others. Genetic forms, caused by inherited gene changes, mainly affect infants and children. Smoking and dust exposure are worth stopping or reducing for anyone with PAP, though how much they contribute to causing the autoimmune form is less certain.
PAP is usually first suspected from a chest CT (computed tomography) scan. The affected lung looks hazy (called ground-glass opacity), often with a pattern of thin lines over the haze that radiologists call "crazy paving." That pattern can also appear with infections, swelling of the lungs and other diseases, so a scan alone does not settle the diagnosis. The key test for the most common form is a blood test for GM-CSF antibodies. A positive result confirms autoimmune PAP and separates it from secondary and genetic forms, and for most people it has replaced the need for a surgical lung biopsy. A bronchoscopy, in which a thin tube is passed into the airways to rinse and collect fluid (bronchoalveolar lavage), can show the surfactant-rich material typical of PAP and can also look for infection. Genetic testing is used when an inherited form is suspected, and a biopsy is kept for unusual cases. Breathing tests and blood oxygen levels show how much the disease is affecting the lungs. The most telling measure is often gas transfer (DLCO, the diffusing capacity), which reflects how well oxygen moves from the air sacs into the blood. It is usually reported as a percentage of the value expected for someone of the same age, sex and size. Lower values mean more of the lung is clogged, and repeat measurements help show whether treatment is working.
Treatment depends on the type of PAP and on how much it is limiting oxygen. People with few or no symptoms and good oxygen levels may only need monitoring, since the disease progresses slowly or stays stable in some people. Stopping smoking, avoiding dust and fumes, and staying current on flu and pneumonia vaccines are recommended for everyone. Whole lung lavage has long been the main treatment for autoimmune PAP when breathing is significantly affected. Under general anesthesia, one lung is repeatedly filled with warm salt water and drained to wash out the built-up material while a machine breathes for the other lung; the second lung is often washed in a separate session. Most people breathe noticeably better soon afterward. Lavage does not fix the underlying antibody problem, though, so surfactant builds up again, and about a third of people need another lavage within two to three years. It is done only at experienced specialist centers. Inhaled GM-CSF aims at the cause: breathing the missing signal directly into the lungs helps the macrophages recover their ability to clear surfactant. It is taken at home with a nebulizer, a device that turns liquid medicine into a mist to breathe in. In randomized trials it improved oxygen transfer and breathlessness compared with placebo, although it did not clearly improve exercise capacity, and international guidelines now treat it as a first-line option for autoimmune PAP, sometimes after a lavage. Molgramostim, the version studied in the largest trials, is not yet approved in the US or elsewhere. Sargramostim (Leukine) is a GM-CSF medicine whose inhaled form is approved for autoimmune PAP in Japan. In the US, sargramostim is approved only as an injection for blood and bone marrow conditions, so using it by nebulizer for PAP is off-label. Availability differs by country and center, so a PAP specialist can explain what is currently possible. For people who do not respond, rituximab (an antibody drug that lowers antibody-producing immune cells) and plasma exchange (filtering antibodies out of the blood) have been tried, but evidence is limited and plasma exchange has to be repeated often. A lung transplant is an option for advanced disease with scarring, though PAP can return in the new lungs. In secondary PAP, treating the underlying condition is the only proven way to improve the lungs, and in genetic forms care is planned by specialist teams.
The course of autoimmune PAP varies widely. In some people it slowly worsens, in others it stays stable for years, and occasionally it settles on its own. With specialist care, many people with autoimmune PAP live a near-normal lifespan. Breathlessness can still limit work, exercise and daily routines, and some people need oxygen during periods when the material has built up again or while waiting for treatment to take effect. PAP is usually a long-term condition rather than a one-time problem. People treated with lavage often go through cycles of improvement followed by a gradual return of symptoms, which is one reason inhaled GM-CSF is increasingly used to extend the time between procedures. Follow-up typically includes breathing tests, oxygen measurements and sometimes imaging, so the care team can spot reaccumulation before it causes serious trouble. Because specialist centers are few, care may involve travel. Autoimmune PAP weakens some of the lungs' defenses, so infections, including unusual ones caused by fungi or bacteria such as Nocardia, are more common and can be more serious. A small number of people develop lung scarring (pulmonary fibrosis), which does not reverse. Secondary PAP has a considerably worse outlook than autoimmune PAP, largely because of the illness behind it.
See a clinician if shortness of breath with activity or a lingering cough keeps getting worse, especially if treatment for asthma, COPD or pneumonia has not helped; asking whether PAP has been considered can shorten a long search for a diagnosis. If you already have PAP, tell your care team when breathlessness slowly returns, exercise becomes harder or home oxygen readings drift lower, since that may mean another treatment is needed. Contact your care team promptly for a fever, coughing up blood, or a new severe headache or confusion, because these can signal an infection, which is more likely and can become serious with PAP. Call 911 if breathing difficulty comes on suddenly or becomes so severe that it is hard to speak.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Pulmonary Alveolar Proteinosis is like, what's helped you, or ask the community a question.